These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9973006)

  • 1. A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials.
    Folts JD; Schafer AI; Loscalzo J; Willerson JT; Muller JE
    J Am Coll Cardiol; 1999 Feb; 33(2):295-303. PubMed ID: 9973006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
    Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist.
    Mousa SA; DeGrado WF; Mu DX; Kapil RP; Lucchesi BR; Reilly TM
    Circulation; 1996 Feb; 93(3):537-43. PubMed ID: 8565173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 8th Seah Cheng Siang Memorial Lecture: new antithrombotic agents.
    Verstraete M
    Ann Acad Med Singap; 1999 May; 28(3):347-62. PubMed ID: 10575518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
    Harrington RA
    Am Heart J; 1999 Oct; 138(4 Pt 2):276-86. PubMed ID: 10502233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic activity of Z4A5, a new platelet glycoprotein IIb/IIIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model.
    Jing BB; Li YX; Zhang H; Ren ST; Wang M; Li YP; Zang WJ; Wang B
    Thromb Res; 2011 Nov; 128(5):463-9. PubMed ID: 21924458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries.
    Maalej N; Folts JD
    Circulation; 1996 Mar; 93(6):1201-5. PubMed ID: 8653842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study.
    Dalby M; Montalescot G; Bal dit Sollier C; Vicaut E; Soulat T; Collet JP; Choussat R; Gallois V; Drobinski G; Drouet L; Thomas D
    J Am Coll Cardiol; 2004 Jan; 43(2):162-8. PubMed ID: 14736431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy.
    Sakariassen KS; Hanson SR; Cadroy Y
    Thromb Res; 2001 Nov; 104(3):149-74. PubMed ID: 11672758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet therapy.
    Schafer AI
    Am J Med; 1996 Aug; 101(2):199-209. PubMed ID: 8757361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [High shear stress induced platelet aggregation (h-SIPA) and effects of antiplatelet therapy].
    Isaka N; Tanigawa T; Nishikawa M; Nakano T
    Nihon Rinsho; 1998 Oct; 56(10):2624-9. PubMed ID: 9796329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of diltiazem on platelet activation and cytosolic calcium during percutaneous transluminal coronary angioplasty.
    Dai H; Chen J; Tao Q; Zhu J; Zhang F; Zheng L; Qiu Y
    Postgrad Med J; 2003 Sep; 79(935):522-6. PubMed ID: 13679549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel antithrombotic drugs in development.
    Verstraete M; Zoldhelyi P
    Drugs; 1995 Jun; 49(6):856-84. PubMed ID: 7641602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of platelet therapy.
    Fry JA; Grines CL
    Semin Interv Cardiol; 2000 Sep; 5(3):117-28. PubMed ID: 11054909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Ferguson JJ; Wilson JM; Diez J
    Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefits of aspirin?
    Théroux P
    Am Heart J; 1997 Nov; 134(5 Pt 2):S62-70. PubMed ID: 9396636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor.
    Frishman WH; Burns B; Atac B; Alturk N; Altajar B; Lerrick K
    Am Heart J; 1995 Oct; 130(4):877-92. PubMed ID: 7572600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.